Search

Your search keyword '"Gisslen M"' showing total 129 results

Search Constraints

Start Over You searched for: Author "Gisslen M" Remove constraint Author: "Gisslen M"
129 results on '"Gisslen M"'

Search Results

2. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.

3. Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

4. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

5. Unbiased serology reveals autoimmunity and HIV antibody signatures in HIV CNS Escape

6. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

7. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

8. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

9. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal

11. Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity

12. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

13. Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

15. Cerebrospinal Fluid Antibodies Directed against Neuron-Associated Gangliosides in HIV-1 Infection

16. Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment

18. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1

19. Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration

21. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

22. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

25. Swedish Covid-19 Investigation for Future Insights – A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL)

26. Laboratory diagnostic value of neopterin measurements in patients with COVID-19 infection

27. Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection

30. Reply to Seligman

32. Updated research nosology for HIV-associated neurocognitive disorders

43. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

45. Clinical Application of Cerebrospinal Fluid Neopterin Concentrations in HIV Infection

46. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

47. Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review

48. Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV

49. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

50. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

Catalog

Books, media, physical & digital resources